Launch Date
07/27/2020
Credit Amount
0.00 Expired
Credit Expires
07/27/2021
Comprehensive patient-centered approaches to opioid therapy, such as integrating non-pharmacologic interventions, can mitigate risks for abuse and diversion of medication. It is imperative that clinicians determine the need for opioids, as they are not first-line or routine therapy for chronic pain, as well as select the appropriate type, dosage, and duration of therapy. To minimize risk of opioid use disorder (OUD) clinicians need to discuss with their patients the importance of opioid tapering and balancing the benefits and risks of long-term opioid therapy.
Part two of this CME Outfitters BriefCase series revisits the patient case from part one, with a focus on how best to handle prescribing, patient education, and shared decision-making via telehealth appointments.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see here for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).
Physicians, dentists, PAs, NPs, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Stanos reports that he is a consultant for Pfizer Inc.; Salix Pharmaceuticals; Sanofi; and SCILEX Pharmaceuticals, Inc.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-107-H08-P.
Call us at 877.CME.PROS (877.263.7767).
BC-020-072720-62